224 related articles for article (PubMed ID: 34330763)
1. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer.
Nam GH; Kwon M; Jung H; Ko E; Kim SA; Choi Y; Song SJ; Kim S; Lee Y; Kim GB; Han J; Woo J; Cho Y; Jeong C; Park SY; Roberts TM; Cho YB; Kim IS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330763
[TBL] [Abstract][Full Text] [Related]
2. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.
Krens LL; Simkens LH; Baas JM; Koomen ER; Gelderblom H; Punt CJ; Guchelaar HJ
PLoS One; 2014; 9(11):e112201. PubMed ID: 25375154
[TBL] [Abstract][Full Text] [Related]
3. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
4. Statin Use After Diagnosis of Colon Cancer and Patient Survival.
Voorneveld PW; Reimers MS; Bastiaannet E; Jacobs RJ; van Eijk R; Zanders MMJ; Herings RMC; van Herk-Sukel MPP; Kodach LL; van Wezel T; Kuppen PJK; Morreau H; van de Velde CJH; Hardwick JCH; Liefers GJ
Gastroenterology; 2017 Aug; 153(2):470-479.e4. PubMed ID: 28512021
[TBL] [Abstract][Full Text] [Related]
5. The KRAS
Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
[TBL] [Abstract][Full Text] [Related]
6. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
7. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L
Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834
[TBL] [Abstract][Full Text] [Related]
8. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation.
Shen CJ; Chan RH; Lin BW; Li NC; Huang YH; Chang WC; Chen BK
Theranostics; 2023; 13(13):4650-4666. PubMed ID: 37649607
[No Abstract] [Full Text] [Related]
9. Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma.
Kwon M; Nam GH; Jung H; Kim SA; Kim S; Choi Y; Lee YS; Cho HJ; Kim IS
Cancer Lett; 2021 Dec; 522():198-210. PubMed ID: 34571082
[TBL] [Abstract][Full Text] [Related]
10. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
11. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
12. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
13. Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of
Padda SK; Aredo JV; Vali S; Singh NK; Vasista SM; Kumar A; Neal JW; Abbasi T; Wakelee HA
JCO Precis Oncol; 2021 Nov; 5():153-162. PubMed ID: 34994595
[TBL] [Abstract][Full Text] [Related]
14. MEK Inhibition Remodels the Immune Landscape of Mutant
Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ERβ/HER Oncogenic Network in
Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514
[TBL] [Abstract][Full Text] [Related]
16. Sourcing the immune system to induce immunogenic cell death in Kras-colorectal cancer cells.
Cirone M; Lotti LV; Granato M; Renzo LD; Biunno I; Cattaneo M; Verginelli F; Vespa S; Davies D; Wells V; Mariani-Costantini R; Mallucci L
Br J Cancer; 2019 Oct; 121(9):768-775. PubMed ID: 31558803
[TBL] [Abstract][Full Text] [Related]
17. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
[TBL] [Abstract][Full Text] [Related]
19. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
20. Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
Kansal V; Burnham AJ; Kinney BLC; Saba NF; Paulos C; Lesinski GB; Buchwald ZS; Schmitt NC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
